The mismanagement of COVID-19 therapeutics by Government, the Media, and Tech – Part 1

 A worthwhile interview of Dr. Peter McCullough, and expert in the COVID-19 saga.

Here is the link to the video.

Here is a link to one of his papers: "Multifaceted highly targeted sequential multidrug treatment of early

ambulatory high-risk SARS-CoV-2 infection (COVID-19)"

Here are the Abstract and Summary.

-------------------------------------------

Abstract

The SARS-CoV-2 virus spreading across the world has
led to surges of COVID-19 illness, hospitalizations, and
death. The complex and multifaceted pathophysiology of
life-threatening COVID-19 illness including viral mediated
organ damage, cytokine storm, and thrombosis warrants
early interventions to address all components of the devastating
illness. In countries where therapeutic nihilism is
prevalent, patients endure escalating symptoms and without
early treatment can succumb to delayed in-hospital
care and death. Prompt early initiation of sequenced multidrug
therapy (SMDT) is a widely and currently available
solution to stem the tide of hospitalizations and death. A
multipronged therapeutic approach includes 1) adjuvant
nutraceuticals, 2) combination intracellular anti-infective
therapy, 3) inhaled/oral corticosteroids, 4) antiplatelet
agents/anticoagulants, 5) supportive care including supplemental
oxygen, monitoring, and telemedicine. Randomized
trials of individual, novel oral therapies have not
delivered tools for physicians to combat the pandemic in
practice. No single therapeutic option thus far has been
entirely effective and therefore a combination is required
at this time. An urgent immediate pivot from single drug to
SMDT regimens should be employed as a critical strategy
to deal with the large numbers of acute COVID-19 patients
with the aim of reducing the intensity and duration
of symptoms and avoiding hospitalization and death.

Summary

The SARS-CoV-2 outbreak is a once in a hundred-year pandemic
that has not been addressed by rapid establishment of infrastructure
amenable to support the conduct of large, randomized
trials in outpatients in the community setting. The early flu-like
stage of viral replication provides a therapeutic window of tremendous
opportunity to potentially reduce the risk of more severe sequelae
in high risk patients. Precious time is squandered with a
"wait and see" approach in which there is no anti-viral treatment
as the condition worsens, possibly resulting in unnecessary hospitalization,
morbidity, and death. Once infected, the only means of
preventing a hospitalization in a high-risk patient is to apply treatment
before arrival of symptoms that prompt paramedic calls or
emergency room visits. Given the current failure of government
support for randomized clinical trials evaluating widely available,
generic, inexpensive therapeutics, and the lack of instructive outpatient
treatment guidelines (U.S., Canada, U.K., Western EU,
Australia, some South American Countries), clinicians must act
according to clinical judgement and in shared decision making
with fully informed patients. Early SMDT developed empirically
based upon pathophysiology and evidence from randomized data
and the treated natural history of COVID-19 has demonstrated
safety and efficacy. In newly diagnosed, high-risk, symptomatic
patients with COVID-19, SMDT has a reasonable chance of therapeutic
gain with an acceptable benefit-to-risk profile. Until the
pandemic closes with population-level herd immunity potentially
augmented with vaccination, early ambulatory SMDT should be
a standard practice in high risk and severely symptomatic acute
COVID-19 patients beginning at the onset of illness.